Clostridium difficile

Global Antimicrobial Resistance Diagnostics Market Report 2023: Availability of Better Diagnostics Tests and Kits Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Health, Biotechnology, AMR, Eyeish, Fungus, Methicillin, Subclinical infection, Bloodstream infections, DRC, Protein, Viral Research and Diagnostic Laboratories, Medication, Bacteria, Public health, Clostridium difficile, Pathogen, Immunoassay, NGS, DNA, Biotechnology, Urinary tract infection, Hospital, DRSP, Microbiology, CD, MRSA, Patient, Staphylococcus aureus, Pneumonia, Infection, Culture, Drug resistance, Catheter, Prevalence, PCR, Healthcare, Vaccine, Antibiotics, Copper

The Global Antimicrobial Resistance Diagnostics Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.

Key Points: 
  • The Global Antimicrobial Resistance Diagnostics Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.
  • Based on end user, the antimicrobial resistance diagnostics market is segmented into hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, and others.
  • The diagnostic laboratories garnered a remarkable growth rate in the antimicrobial resistance diagnostics market in 2021.
  • The North America segment procured the maximum revenue share in the antimicrobial resistance diagnostics market in 2021.

SpectrumX’s Hand Sanitiser Approved for NHS Supply Chain’s NHS Supplier List

Retrieved on: 
Thursday, December 1, 2022
Pharmaceutical, Health, Medical Supplies, RADIUS, NHS Supply Chain, Skin, London Stock Exchange, Hypochlorous acid, Degenerative disease, GP, Clostridium difficile, Trust law, Bacteria, Health, Plastic, Spore, Fungus, IPO, London, Letter, Interest, Virus, Yeast, Water, Hand washing, NHS, Human, Infection, Pharmaceutical industry, Health insurance, Vaccine, Tuberculosis

As a result, SpectrumX will be awarded a tender framework agreement to become an approved NHS supplier, allowing NHS healthcare facilities to purchase the Companys patent-pending hand sanitiser.

Key Points: 
  • As a result, SpectrumX will be awarded a tender framework agreement to become an approved NHS supplier, allowing NHS healthcare facilities to purchase the Companys patent-pending hand sanitiser.
  • NHS Supply Chain is a logistics company that manages the sourcing, delivery, and supply of healthcare and food products to the NHS and other healthcare organisations in England and Wales.
  • Buyers and procurement teams at NHS Trusts, GP and dentistry surgeries, care homes, and other facilities purchase through the NHS Supply Chain catalogue.
  • Damien Hancox, CEO of SpectrumX, said: We are thrilled that weve succeeded, through this rigorous tender process, in becoming an approved NHS supplier with NHS Supply Chain.

Research Study Confirms Efficacy of Doctor's Biome Signature Probiotics Blend

Retrieved on: 
Wednesday, November 16, 2022
Technology, Leadership, Chief technology officer, News, FDA, Patent, CEO, Newgen, GI, Probiotic, LLC, Unit, Clostridium difficile, Science and technology, Dietary supplement

HAUPPAUGE, N.Y., Nov. 16, 2022 /PRNewswire/ -- A new in vitro research study conducted by the Eurofins Labs confirmed efficacy of Doctor's Biome proprietary blend of probiotics (10 lactobacilli and 5 bifidobacteria) in inhibition of Clostridium difficile (C. diff); a life-threatening diarrhea-causing bacteria.

Key Points: 
  • HAUPPAUGE, N.Y., Nov. 16, 2022 /PRNewswire/ -- A new in vitro research study conducted by the Eurofins Labs confirmed efficacy of Doctor's Biome proprietary blend of probiotics (10 lactobacilli and 5 bifidobacteria) in inhibition of Clostridium difficile (C. diff); a life-threatening diarrhea-causing bacteria.
  • "We would like to name this proprietary blend of 15 probiotic bacteria Doctor's Biome Signature Probiotic Blend."
  • Doctors Biome just filed a patent application for its Signature Probiotics Blend.
  • So far, we thought we had a unique technology to offer living probiotics in a blend of organic vegetable-fruit juice but we now know that we also have a signature probiotic blend.

 Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs

Retrieved on: 
Monday, November 7, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Symptoms of COVID-19, Therapy, Clostridioides difficile (bacteria), Recurrence, CDC, Centers for Disease Control and Prevention, CDI, Multimedia, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Șaeș, ClinicalTrials.gov, Clostridioides difficile infection, Clostridioides, FDA, Variometer, Safety, Incidence, AES, CD3, Center, Ferring Pharmaceuticals, PUNCH, Nausea, Fever, Medication, Risk, Health, Diarrhea, Hospital, CP, Inflammation, Journal of Managed Care & Specialty Pharmacy, Maternal health, Reproductive medicine, Gastroenterology, Colitis, Diagnosis, Patient, Pain, Clostridium difficile, Mayo Clinic, Pharmaceutical industry, Medical device, Dietary supplement, Animal

RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent CDI (rCDI) after antibiotic treatment.

Key Points: 
  • RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent CDI (rCDI) after antibiotic treatment.
  • The published manuscript, titled, Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial With a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection is available online .
  • Participants were followed up to eight weeks for the primary efficacy analysis, and up to six months for efficacy and safety analyses.
  • Participants were followed up to eight weeks for the efficacy analysis, and up to 24 months for the safety analysis.

Global Infectious Diseases Partnering Deal Trends, Players and Financials Analysis Report 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 25, 2022
Health, Infectious Diseases, Campylobacter jejuni, MRSA, SEC, Directory, Review, Yellow fever, Salmonella, Global Infectious Disease Epidemiology Network, Chapter Three, Chapter One, Respiratory syncytial virus, Orientation, Contract, RSV, Chapter Five, Research, Anthrax, FIV, Methicillin-resistant Staphylococcus aureus, Escherichia coli, Technology, Haemophilus influenzae, Common cold, HIV, Chapter Six, Foot, Chapter Two, Herpes simplex, Dengue fever, A-Z, Tetanus, Mycobacterium avium complex, Streptococcus, Clostridium difficile, Hepatitis A, Lyme disease, Chapter Four, Pseudomonas aeruginosa, African trypanosomiasis, Hyperlink, Helicobacter pylori, TB, Vaccine, Pharmaceutical industry, Haemophilus, West Nile virus, Infection, Tuberculosis, H1N1, Zika fever, Sepsis, Cytomegalovirus, Diphtheria, Malaria

The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 2,900 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2015.

Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022

Retrieved on: 
Tuesday, October 11, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, LinkedIn, CDC, AGAF, MBBS, Risk, Yale School of Medicine, Nausea, Therapy, CP, Maternal health, Breakthrough therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Reproductive medicine, Diarrhea, CDI, Twitter, Clostridioides difficile infection, Division, FACG, Multimedia, Fridtjof Nansen Prize for Outstanding Research, Inflammation, Centers for Disease Control and Prevention, Food, Center, ACG, MD, Journal of Managed Care & Specialty Pharmacy, Symptoms of COVID-19, Health, Pain, Ferring Pharmaceuticals, Research, Hepatology, Congress, Safety, EDT, 2021 Essex County Council election, Medication, Recurrence, Fast Track, Fever, Clostridium difficile, Death, Colitis, FDA, American College, Pharmaceutical industry, Medicine, Perfume, Animal, Gastroenterology, Patient

Ferring Pharmaceuticals today announced it will present data from new analyses of RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.

Key Points: 
  • Ferring Pharmaceuticals today announced it will present data from new analyses of RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.
  • In addition, data will be presented that measures the physical, mental, and social health-related quality of life in patients with recurrent CDI.
  • C. difficile infection (CDI) is a serious and potentially deadly disease that impacts people across the globe.
  • Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection.

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

Retrieved on: 
Thursday, September 22, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, Clostridioides difficile infection, Symptoms of COVID-19, Health, Inflammation, Therapy, Ferring Pharmaceuticals, Saint-Prex, Safety, Incidence, Center, Twitter, Risk, MD, FDA, Food, Diarrhea, LinkedIn, CP, FACG, Yale School of Medicine, AGAF, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Breakthrough therapy, Maternal health, Gastroenterology, Colitis, Pain, CDC, Centers for Disease Control and Prevention, Journal of Managed Care & Specialty Pharmacy, Medication, Diagnosis, Vaccine, Fast Track, Death, Committee, Research, BLA, Nausea, Fever, Reproductive medicine, Multimedia, Clostridium difficile, Urology, CDI, Recurrence, Mother, Pharmaceutical industry, Medical device, Animal, Ferring

The advisory committee provides recommendations to the FDA, which the agency may consider but is not required to follow, when making its decision.

Key Points: 
  • The advisory committee provides recommendations to the FDA, which the agency may consider but is not required to follow, when making its decision.
  • The committees vote is a step toward potentially addressing the debilitating cycle of recurrence and the suffering faced by these patients.
  • The clinical development program for RBX2660 included six studies with a total of 1061 participants, of which 978 were treated with RBX2660.
  • RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA).

Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic

Retrieved on: 
Tuesday, August 9, 2022
Health, FDA, Research, Pharmaceutical, Science, Biotechnology, FDA, Saint-Prex, Regulation of tobacco by the U.S. Food and Drug Administration, Multimedia, Nausea, Risk, Urology, Colitis, Maternal health, Inflammation, Recurrence, Death, Journal of Managed Care & Specialty Pharmacy, Diagnosis, CDI, YouTube, Center, Breakthrough therapy, Research, Pain, Diarrhea, Clostridioides difficile infection, Fever, CDC, Review, Patient, Reproductive medicine, Twitter, Therapy, Centers for Disease Control and Prevention, Ferring Pharmaceuticals, BLA, Vaccine, Medication, Gastroenterology, Fast Track, LinkedIn, Mother, CP, Food, Health, Clostridium difficile, Symptoms of COVID-19, Pharmaceutical industry, Medical device, Animal, Ferring

The cycle of recurrent CDI represents a significant public health burden, and Ferring is working to address that unmet need.

Key Points: 
  • The cycle of recurrent CDI represents a significant public health burden, and Ferring is working to address that unmet need.
  • The FDA intends to live stream the advisory committee meeting on the agency's YouTube page, and the meeting will also be webcast from the FDA website.
  • RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA).
  • Ferring Pharmaceuticals is a research driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.

Paradigm Convergence Technologies Corporation’s Hydrolyte® can be used to kill Monkeypox virus

Retrieved on: 
Wednesday, June 1, 2022
Manufacturing, Infectious Diseases, Environment, Health, Chemicals, Plastics, Lorton station (VRE), United States Environmental Protection Agency, Toxicity, Goal, Company, Phenols, Precautionary principle, PCTL, FAC, Nursing, Regulation, HAI, Disinfectant, Technology, Severe acute respiratory syndrome coronavirus 2, Family, Volatile organic compound, EPA, Cres, EVP, Hypochlorous acid, Eating, Health, Securities Exchange Act of 1934, Clostridium difficile, Securities Act of 1933, Clostridioides difficile infection, HIV, PCT, COVID-19, Contract, TB, Monkeypox virus, Physician, Patient, DNA, SEC, Virus, Greasy, School, ECA, Disease, PPE, CDC, Chlorine, Water, MRSA, Bacteria, Vaccine, Monkeypox, Norovirus

Monkeypox is caused by the Monkeypox virus, an enveloped double-stranded DNA virus which belongs to a group of viruses that is more susceptible to disinfectants than other types of viruses.

Key Points: 
  • Monkeypox is caused by the Monkeypox virus, an enveloped double-stranded DNA virus which belongs to a group of viruses that is more susceptible to disinfectants than other types of viruses.
  • While there are no disinfectants registered for use against monkeypox, all products with EVP claims have been tested against viruses that are more difficult to kill than monkeypox.
  • EPA expects products on its List of Disinfectants for Emerging Viral Pathogens to kill monkeypox when used according to the label directions.
  • The company acquires and holds rights to innovative products and technologies, which are commercialized through its owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp).

Diabetes-Related Mechanisms of Action Make Their Move as Several NAFLD/NASH Pipeline Therapies Inch Closer to the First-Ever FDA Approval, Spherix Reports

Retrieved on: 
Wednesday, June 1, 2022
PPAR, American Gastroenterological Association, EOE, NAFLD, Primary biliary cholangitis, CCP, PBC, Patient, Clostridium difficile, Review, AGA, CED, Nephrology, Gastroenterology, Eosinophilic esophagitis, Degenerative disease, Pharmaceutical industry

EXTON, Pa., June 1, 2022 /PRNewswire/ -- Spherix recently surveyed 103 US gastroenterologists and 20 hepatologists, along with conducting eight qualitative interviews (including 2 KOLs and 6 clinical trial participants), to assess the current and future management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • Quantitative data captured for these NAFLD/NASH pipeline therapies includes:
    These metrics in the Spherix report can help to identify where the NAFLD/NASH market is moving in terms of expectations for pipeline therapies and their mechanisms of action.
  • For example, the American Gastroenterology Association (AGA) recently established a Critical Care Pathway (CCP) for diagnosing and managing NAFLD/NASH patients.
  • This revised approach also appears to be influencing gastroenterologists' and hepatologists' prioritization of the pipeline therapies with diabetes-focused mechanisms.
  • Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.